Edition:
India

Danaher Corp (DHR.N)

DHR.N on New York Stock Exchange

141.35USD
9:34pm IST
Change (% chg)

$0.34 (+0.24%)
Prev Close
$141.01
Open
$140.75
Day's High
$141.90
Day's Low
$140.75
Volume
84,341
Avg. Vol
713,151
52-wk High
$141.90
52-wk Low
$94.62

Latest Key Developments (Source: Significant Developments)

FDA Alerts About Recall Of Beckman Coulter Blood Test Analyzers
Thursday, 23 May 2019 

May 23 (Reuters) - U.S. Food and Drug Administration::FDA - ALERTS ABOUT RECALL OF BECKMAN COULTER BLOOD TEST ANALYZERS DUE TO RISK OF INACCURATE PLATELET ANALYZING RESULTS.FDA - HAS NOT RECEIVED REPORTS OF SERIOUS ADVERSE EVENTS LINKED DIRECTLY TO BECKMAN COULTER HEMATOLOGY ANALYZERS.FDA SAYS ALERTING HOSPITALS, LABORATORIES & PROVIDERS OF A CLASS 1 RECALL OF BECKMAN COULTER DXH 800, DXH 600 & DXH 900 HEMATOLOGY ANALYZERS-DEVICES.  Full Article

Third Point Cuts Share Stake In Constellation Brands
Thursday, 16 May 2019 

May 15 (Reuters) - THIRD POINT LLC::THIRD POINT LLC CUTS SHARE STAKE IN CONSTELLATION BRANDS INC BY 40.0 PERCENT TO 1.1 MILLION CLASS A SHARES - SEC FILING.THIRD POINT LLC TAKES SHARE STAKE OF 2.0 MILLION SHARES IN CHEMOURS CO.THIRD POINT LLC UPS SHARE STAKE IN DANAHER CORP BY 19.3 PERCENT TO 3.7 MILLION SHARES.THIRD POINT LLC: CHANGE IN HOLDINGS ARE AS OF MARCH 31, 2019 AND COMPARED WITH THE PREVIOUS QUARTER ENDED AS OF DECEMBER 31, 2018.  Full Article

Danaher Reports Q1 Adjusted Non-GAAP Earnings Per Share $1.07
Thursday, 18 Apr 2019 

April 18 (Reuters) - Danaher Corp ::DANAHER REPORTS FIRST QUARTER 2019 RESULTS.SEES Q2 2019 ADJUSTED NON-GAAP EARNINGS PER SHARE $1.13 TO $1.16.SEES FY 2019 ADJUSTED NON-GAAP EARNINGS PER SHARE $4.72 TO $4.80.SEES Q2 2019 EARNINGS PER SHARE $0.89 TO $0.92.SEES FY 2019 EARNINGS PER SHARE $3.34 TO $3.42.Q1 ADJUSTED NON-GAAP EARNINGS PER SHARE $1.07.Q1 EARNINGS PER SHARE $0.46.Q1 REVENUE $4.9 BILLION VERSUS REFINITIV IBES ESTIMATE OF $4.79 BILLION.Q1 EARNINGS PER SHARE ESTIMATE $1.02 -- REFINITIV IBES DATA.Q2 EARNINGS PER SHARE VIEW $1.19, REVENUE VIEW $5.08 BILLION -- REFINITIV IBES DATA.FY2019 EARNINGS PER SHARE VIEW $4.79, REVENUE VIEW $20.55 BILLION -- REFINITIV IBES DATA.UPDATED FY GUIDANCE REFLECTS DILUTION RELATED TO RECENT EQUITY OFFERINGS TO FUND GE BIOPHARMA ACQUISITION.  Full Article

GE Withdraws Plans For Healthcare IPO After Danaher Deal - CNBC, Citing Bloomberg
Monday, 25 Feb 2019 

Feb 25 (Reuters) - :GE WITHDRAWS PLANS FOR HEALTHCARE IPO AFTER DANAHER DEAL - CNBC, CITING BLOOMBERG.  Full Article

Beckman Coulter Diagnostics Announces Worldwide Commercialization Of The Access Sensitive Estradiol
Tuesday, 10 Apr 2018 

April 10 (Reuters) - Beckman Coulter Diagnostics::BECKMAN COULTER DIAGNOSTICS ANNOUNCES WORLDWIDE COMMERCIALIZATION OF THE ACCESS SENSITIVE ESTRADIOL.  Full Article

Danaher Reports Q4 EPS Of $1.21
Tuesday, 30 Jan 2018 

Jan 30 (Reuters) - Danaher Corp ::DANAHER REPORTS FOURTH QUARTER AND FULL YEAR 2017 RESULTS.SEES Q1 2018 ADJUSTED NON-GAAP EARNINGS PER SHARE $0.90 TO $0.93.SEES FY 2018 ADJUSTED NON-GAAP EARNINGS PER SHARE $4.25 TO $4.35.SEES FY 2018 EARNINGS PER SHARE $3.50 TO $3.60.SEES Q1 2018 EARNINGS PER SHARE $0.71 TO $0.74.Q4 ADJUSTED NON-GAAP EARNINGS PER SHARE $1.19.Q4 EARNINGS PER SHARE $1.21.Q4 REVENUE $5.1 BILLION VERSUS I/B/E/S VIEW $4.96 BILLION.Q4 EARNINGS PER SHARE VIEW $1.15 -- THOMSON REUTERS I/B/E/S.‍CONTINUES TO EXPECT ITS 2018 NON-GAAP ADJUSTED DILUTED NET EARNINGS PER SHARE TO BE IN RANGE OF $4.25 TO $4.35​.FY2018 EARNINGS PER SHARE VIEW $4.35, REVENUE VIEW $19.17 BILLION -- THOMSON REUTERS I/B/E/S.Q1 EARNINGS PER SHARE VIEW $0.93, REVENUE VIEW $4.48 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Danaher Sees FY 2018 Adjusted Earnings Per Share $4.25 To $4.35
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Danaher Corp ::DANAHER INITIATES 2018 OUTLOOK.SEES FY 2018 EARNINGS PER SHARE $3.50 TO $3.60.SEES FY 2018 ADJUSTED NON-GAAP EARNINGS PER SHARE $4.25 TO $4.35.FY2018 EARNINGS PER SHARE VIEW $4.34, REVENUE VIEW $19.09 BILLION -- THOMSON REUTERS I/B/E/S.- SEES 2018 NON-GAAP CORE REVENUE GROWTH BETWEEN 3.5 PERCENT AND 4 PERCENT.  Full Article

Danaher Announces Leadership Appointment
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Danaher Corp ::DANAHER ANNOUNCES LEADERSHIP APPOINTMENT.DANAHER CORP - ‍BOARD OF DIRECTORS IS APPOINTING JOAKIM WEIDEMANIS TO POSITION OF EXECUTIVE VICE PRESIDENT OF DANAHER CORPORATION​.DANAHER CORP - ‍WITH THIS APPOINTMENT, WEIDEMANIS WILL BECOME AN EXECUTIVE OFFICER OF COMPANY​.  Full Article

Quidel Says Confident In Validity Of Supply Agreement With Beckman Coulter To Sell BNP Assay Assets
Monday, 27 Nov 2017 

Nov 27 (Reuters) - Quidel Corp ::QUIDEL CONFIDENT IN LEGAL STRENGTH AND VALIDITY OF SUPPLY AGREEMENT WITH BECKMAN COULTER TO SELL BNP ASSAY ASSETS.CO ‍ACKNOWLEDGED BECKMAN COULTER PLANS TO PURSUE COMMERCIAL LITIGATION TO ALLOW IT TO SELL BNP DIRECTLY.‍IN RECENT WEEKS, BOARD REJECTED OFFERS BY DANAHER CORP TO BUY BNP ASSAY BUSINESS​.‍BOARD FOUND THAT DANAHER'S PROPOSAL WAS "INADEQUATE" FOR BNP ASSAY BUSINESS​.  Full Article

IDBS says has been acquired by Danaher Corp
Monday, 30 Oct 2017 

Oct 30 (Reuters) - :U.K's IDBS says has been acquired by the life sciences platform of Danaher Corp.  Full Article

Photo

GE inks $21 billion biopharma sale to Danaher in U-turn under Culp

General Electric said on Monday it would sell its biopharma business to Danaher Corp for $21.4 billion in the biggest strategy reversal since Lawrence Culp took over as the industrial conglomerate's chief executive in September. | Video